



14TH AIS Antibody **2026** Industrial Symposium

JUNE 30-JULY 1, 2026
MONTPELLIER, FRANCE

Post-Event Report

Executive Summary



+550
Participants



+550 B2B
Meetings



+270
Organizations



58
Sponsors/Exhibitors



76
Speakers



20
Countries



80
Posters

AIS is a high-value antibody community meeting with measurable satisfaction, visibility and networking outcomes. The feedback confirms a strong scientific core and a clear client-facing opportunity.

+62

Net Promoter Score

Strong participant recommendation & advocacy

84%



Likely to attend again next year

8.9/10

Recommend AIS

"AIS is becoming a flagship event in the antibody community, featuring internationally renowned speakers."

Representative attendee testimonial from the feedback survey



"Great networking possibilities." "Quality of the attendance". "Easy to meet everybody".

Representative attendee testimonial from the feedback survey

OUR STORY

In order to provide to the scientists involved in research on therapeutic antibodies, a comprehensive view about topics of interest for the pharmaceutical industry the LabEx MAbImprove started the **Antibody Industrial Symposium** in 2013.

Here are the previous editions:

1st Antibody Industrial Symposium (AIS2013) – May 28 in Tours, 2013 – *“Antibody Biosimilars”*

2nd Antibody Industrial Symposium (AIS2014) – July 3 in Montpellier, 2014 – *“MAbDosing”*

3rd Antibody Industrial Symposium (AIS2015) – July 2 in Tours, 2015 – *“MAbDelivery”*

4th Antibody Industrial Symposium (AIS2016) – July 4-5 in Montpellier, 2016 – *“Current and Next Generation Antibody Formats”*

5th Antibody Industrial Symposium (AIS2017) – June 27-28 in Tours, 2017
“ADCs – Design & Development for Therapy and Imaging in and beyond Cancer”

6th Antibody Industrial Symposium (AIS2018) – June 25-26 in Montpellier, 2018
“TARGETS FOR MABS: Innovative Approaches for their Discovery & Validation”

7th Antibody Industrial Symposium (AIS2019) – June 24-25 in Tours, 2019
“Harnessing the Immune System with Therapeutic Antibodies”

8th Antibody Industrial Symposium (AIS2020) – November 23-24 2020, Virtual format
“Multispecific Antibodies, Ab-like Molecules & Adoptive Cell Therapy for Fighting Diseases”

9th AIS (AIS2021) – June 22-25 2021, Virtual format

10th AIS(AIS2022) – June 28-29 in Montpellier, 2022 – **ANNIVERSARY EDITION**

11th AIS(AIS2023) – June 22-23 in Tours, 2022 – *Parallel Tracks on therapeutic Abs and Cell & Gene Therapy*

12th AIS(AIS2024) – June 20-21 in Montpellier, 2024 – *Next generation of Abs & New modalities*

13th AIS(AIS2025) – June 25-26 in Tours, 2025 – *Discovery & Optimization of Abs and derivatives, Next-Gen*

14th AIS(AIS2026) – June 30-July 1 in Montpellier, 2026 – *Advanced Antibody Modalities for Precision Medicine*

SAVE THE DATE

SAVE THE DATE

15TH AIS 2027 Antibody Industrial Symposium

JUNE 23-24 2027
TOURS, FRANCE

MAbImprove
mabdesign

Since the 4th edition of AIS2016, MabDesign has joined forces in the organization of this congress, bridging academia and industry. Since 14 years, the AIS has allowed to gather more than **4680+ Participants** from **23 different countries**, **629+ Expert Speakers**, held **4620+ B2B meetings**, presented **124 Pitches**, **495+ posters** and **391 Exhibitors/Sponsors** showcase their latest innovations, in the field of therapeutic antibodies, recombinant proteins and other biotherapeutics research and development.

WHO ATTENDED IN 2026 ?

KEY FIGURES

- ✓

550+

participants from 20 different countries
- ✓

550+

BtoB meetings took place
- ✓

270+

different organizations present
- ✓

58


Exhibitors and Sponsors
- ✓

76


High-profile Speakers
- ✓

80

Poster presentations



WHERE FROM?




2026 SPONSORS & EXHIBITORS



2026 SUPPORTED BY



2026 PARTNERS



THE 2026 AGENDA

Pre-Event

Monday, June 29th 2026

1:30PM - 7:00PM

Pre-Event by  **evotec**

From Antibody Discovery to IND: Advancing Biologics in Oncology

An Evotec science event held in conjunction with AIS 2026

Antibodies and related modalities have transformed oncology through advances in engineering and a deeper understanding of cancer biology and immune surveillance. This event will feature **invited lectures from internationally recognized leaders alongside Evotec experts** covering integrated biologics discovery, antibody profiling, pharmacokinetics, and ADC strategies.

The half-day, science-focused event will take place ahead of the Antibody Industrial Symposium and provides an opportunity for in-depth scientific exchange and discussion.

Agenda

- 13h30

Registration and welcome coffee
- 14h05

OPENING KEYNOTE LECTURE - Barthez Auditorium

Mining Antibody Biology for Novel Functionalities and Therapeutic Antibody Development





Janine Schuurman
Independent biotech Consultant
Lust for Life Science, Netherlands

14h35

INTRODUCTION - Barthez Auditorium

Integrated Drug Discovery Continuum at Evotec





Francisco Cruzalegui
SVP Biology
EVOTEC





Sophie Venet
Senior Research Scientist - In Vitro Biology
EVOTEC





Clémence Mondielli
Research Scientist - Biophysics
EVOTEC





Anne Larvor
Group Leader - Bioservices and Welfare
EVOTEC

15h45

Antibody-Drug Conjugates (ADCs) Drug Discovery






Christophe Boldron
VP - Head of Molecular Architects
EVOTEC

16h00

Coffe Break with pastries

7



14TH AIS Antibody
Industrial
Symposium
2026

From Antibody Discovery to IND: Advancing Biologics in Oncology

An Evotec science event held in conjunction with AIS 2026.

CORUM Congress Center, Montpellier | 29 June 2026 | 1:30 pm - 7:00 pm CET



Register Now

16h30

Late Antibody Discovery - Barthez Auditorium

Pharmacological Support for Antibody Discovery - Immune Synapse



Michael Esquerre
VP Immuno-Oncology - In Vitro Biology
EVOTEC

Humanized Mouse Models Supporting Antibody Profiling



Lise Pasquet
Senior Research Scientist - Immuno-Oncology In Vivo
EVOTEC

Production, Early Developability Assessment and Affinity Maturation in Antibody Drug Discovery



Ewa Pilka
Principal Scientist - Protein Sciences
EVOTEC

17h15

Just's Molecular Design and Manufacturing Platform




Nick Hutchinson
Associate VP - Business Development
JUST - EVOTEC BIOLOGICS

17h30

CLOSING LECTURE


How Antibody-Based Therapies Were Game Changers in the Treatment of Patients With Hematologic Cancers



Prof. Guillaume Cartron
PU-PH - Head of the Clinical Hematology Department
Montpellier University Hospital, France

18h00

Cocktail reception and informal networking



AGENDA

Pre-Event Site Tour INITS SMO Day 1 Day 2

Site Tour of INITS SMO

 Monday, June 29th 2026
 4:00PM - 7:00PM



14TH AIS Antibody
Industrial
Symposium
2026

Explore our R&D and GMP facilities!



29 June 2026
4:00 PM to 7:00 PM
Shuttle from Le Corum

[Register Now](#)


Join us for an exclusive site tour of INITS SMO!

INITS invite you for a guided tour of **INITS SMO** (Shared Manufacturing Organization), our 3,200 m² multiproduct and flexible GMP biomanufacturing facility, designed to accelerate your innovative products and processes.

This event will take place on **Monday, June 29, from 4:00 PM to 7:00 PM**, with **shuttle departures from Le Corum in Montpellier**.

Ideal for biotechs, pharma companies, startups, and bioproduction stakeholders, this is your opportunity to explore our cutting-edge R&D and GMP facilities.

Reserve your spot today! We look forward to welcoming you.



THE 2026 AGENDA

Day 1

Tuesday, June 30th 2026

8h00

Registration and welcome coffee

8h50

OPENING KEYNOTE LECTURES - Einstein Auditorium

8h50 • *The estate of in vitro antibody discovery*



James Marks

Professor Emeritus

University of California San Francisco, USA

9h15 • *Beyond oncology: is the antibody field underexploited?*



Elsa Kress

Head of Business Development

MabDesign, France

9h30 •

CMC regulatory considerations in the design, development and quality of therapeutic and diagnostic monoclonal antibodies and related products




Marjorie A. Shapiro

Retired FDA

FDA, USA

10h00

Coffee Break at Exhibition Hall



10h30

Advanced Antibody Modalities for Precision Oncology

- Einstien Auditorium

10h30 • **Multilink technology to generate high DAR and dual-payload ADCs**



Olivier Cochet

Head of Pharmaceutical Development

Debiopharm International, Switzerland

11h00 • **Tumor selective CD47 targeting for the treatment of solid tumors**



Nicolas Fischer

CEO

Lightchain Bioscience, Switzerland

11h30 • **Ab discovery (in silico). Electronic and Atomic Protein Modelling**



Victor Guallar Tasies

Electronic and Atomic Protein Modelling Group Manager

Barcelona Supercomputing Center, Spain

12h00 • **Quick 'n' Clean - Innovative HTP BsAb Production for Optimal Pairing Screening at Discovery Stage**



Winfried Elis

Senior Manager, CRO Services

WuXi Biologics, Germany

12h20 • Lunch at Exhibition Hall

Masked and Activatable Antibodies : New Paradigms in Targeted Therapeutics

- Barthez Room

10h30 • **Rewriting therapeutic selectivity: the rise of conditionally active biologics**



Benjami Oller Salvia

Associate Professor - ERC Grantee Department of Bioengineering

IQS, Universitat Ramon Llull, Spain

11h00 • **In vivo tumor pH imaging as a new tool for evaluating anticancer therapies**



Dario Livio Longo

Head, Research Unit at IBB-CNR

National Research Council of Italy (CNR), Italy

11h30 • **Clinical reality surrounding hypermetabolism and tumor acidity**



Guillaume Cartron

University Professor, Head of the Clinical Hematology Department

CHU Montpellier, France

12h00 • **Next-generation TCR-like antibodies with improved specificity profiles**



André Frenzel

CSO

YUMAB, Germany

12h10 • **Enabling Antibody Discovery Research: Transmembrane Protein Technologies, TR-FRET-based Screening Assays and Sustainable Safety Testing Solutions**




Idil Ariöz

Technical Sales Supervisor, West-South Europe

ACROBiosystems, Switzerland

12h20



THE 2026 AGENDA

14h00

Innovative Antibody Formats for Therapy

- Einstein Auditorium

14h00 • **Engineering of multifunctional antibody derivatives for targeted immunomodulation in the context of autoimmune pulmonary alveolar proteinosis (aPAP)**

MERCK



Stefan Zielonka

Prof. Dr., Global Head of Antibody Discovery & Protein Engineering (ADPE)
Merck Healthcare KGaA, Germany

14h30 • **Biologics for targeted protein degradation**

sanofi



Sufyan Sayyed

Project Head Innovation – Principal Scientist II Large Molecules Research, NANOBODY® Research Platform

SANOFI, Belgium

15h00 • **KnotBody® molecules: Chimeric fusions of knottins in antibody CDR loops for modulating GPCR and ion channel function**

maxiontherapeutics



Mark Bushell

Director of Technology

Maxion Therapeutics, UK

15h30 • **High-Throughput Platform for AI-Derived Antibody Drug Identification and Developability Assessment**

Sino Biological



Yu-Chih Lin

Technical specialist

Sino Biological, Germany

Targeting Tumor Microenvironment with pH-Sensitive Antibodies

- Barthez Room

14h00 • **Engineering pH-dependent Antibodies**

ircm



Pierre Martineau

Team Leader - Functional screening and targeting in cancer

Institut de Recherche en Cancérologie Montpellier (IRCM), France

14h30 • **Conditionally Activated Antibodies for Solid Tumors: Concepts and Design Rationale from VISTA-Targeted pH-Selective and Bispecific Immunomodulators**

sensei BIO



Edward Van Der Horst

Formerly CSO Sensei Bio

Sensei Bio, USA

15h00 • **Next-Generation Tumor-Specific Anti-CD30 ADC as a New Therapy in Hemato-Oncology**

Mabq



Johanna Marines

Head of Preclinical

Mabq, France

15h30 • **Capturing the Full Experimental Picture: Why Structure and Context Matter in Biologics Data**

IDBS




Satyalakshmi Druganty

Lead Solutions Consultant

IDBS, UK

15h40

Coffee Break at Exhibition Hall




16h00

Pitch Session : Innovative Approaches and New trend Technologies

- Einstein Auditorium

16h00 • **Towards True Sub-nM Affinity Readouts in SPR with K-One Surface Chemistry**



Alexandra Frommlet
Project Leader
Kimialys, France

16h10 • **Novel Fc-Engager proteins as targeted approach for antigen-specific immune inhibition**



Jochen Stritzker
CEO & CSO
LoopLab Bio GmbH, Germany

16h20 • **A novel bispecific nanobodies conjugates to inhibit IFNAR signaling in tumor cells and increase replication of oncolytic virus**



Mireia Pelegrin
Research Director CNRS Group Leader « Antibodies and Immunomodulation »
IRMB-INSERM U1183-CHU Saint Eloi, France

16h30 • **MQI-201: A Pan-Cancer Immunotherapy Targeting TRPV6 to Convert Cold Tumors Into Hot Tumors**



Lindsay Alcaraz
Senior Scientist - Vivo Preclinical Manager
Mabqi, France

Developability, Analytics & Quality of Antibodies and ADCs

- Barthez Room

16h00 • **Innovative NMR Methods for High-Resolution HOS Characterization of Therapeutic mAbs in Development**



Oriane Frances
Senior Scientist in Structural Biology and Biophysics
SANOFI, France

16h30 • **The Evolution of LC-MS Workflows for Characterizing ADCs and Complex Biologics: Case Studies and New Insights**




Dan Bach Kristensen
Scientific Director
Servier Symphogen, Denmark

17h00 • **Optimizing Developability of Multispecific Antibodies through Charge Engineering**




Andreas Evers
Scientific Director
Merck KGaA, Germany

17h30 • **No Handoffs: End-to-End Analytical and Bioanalytical Expertise for ADC Development**



Loïc Bousser
Key Account Manager
Quality Assistance, Belgium



16h40 • *High-Resolution NMR Methods for Structural Quality Assessment of Therapeutic mAbs*



Faustine Henot

Post-Doc Researcher

Integrated Drug Discovery / BioStructure and Biophysics, SANOFI, France

16h50 • *Towards a generalizable strategy for biotherapeutic conditional activation : de novo mask design for the rapid generation of activatable miniprotein binders*



Montserrat Escobar-Rosales

Predoctoral Researcher

IQS, Universitat Ramon Lull, Spain

17h00 • *Harnessing Cathepsin D to boost anti-tumor immunity and next-generation antibody-based therapies*



Emmanuelle Liaudet-Coopman

Senior Scientist

Institut Régional du Cancer de Montpellier (ICM), Ircm, France

17h10 • *SPARC-Targeted Antibody-Drug Conjugates for Dual Targeting of Tumor Cells and Stroma in Solid Cancers*



Ilona Berestjuk

Post-doctoral Researcher

IRCM, INSERM-U1194, France

17h20 • *Preclinical 3D-Living System of Central Nervous System to accelerate discovery of new drugs against neurological diseases*



Amandine Roux

President & CEO

Research PIECES, France


17h30 • *ArchShield: a scaffold-based approach to discover binders against structurally challenging extracellular epitopes of GPCRs*



Xavier Leroy

CEO

ArchShield Therapeutics, France



17h40

From Bench to Bedside: Integrating Perspectives for Oncology Antibody Development

- Einstein Auditorium



Laurent Gros
Senior Scientist
IRCM, France



Rosie Dawaliby
Co-founder & CEO
G-CLIPS, France



Stanislas Quesada

Medical Oncologist & Scientist

Institut Régional du Cancer de Montpellier (IRC), IRCM, France



Olivier Cochet

Head of Pharmaceutical Development

Debiopharm International, Switzerland



Moderated by:

Elsa Kress

Head of Business Development

MabDesign, France

ENOTTA Session : Assessment of Immunogenicity and Personalized Dose Adjustment for mAbs - Toward New Horizons

- Barthez Room



Denis Mulleman

Action Chair

European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA), France

17h40 • **Updates from COST Action ENOTTA (European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases)**




George Kararigas

Professor

University of Nicosia - Athens, Greece

18h00 • **A Chemiluminescent Point-of-Care Platform for Therapeutic Drug Monitoring of Infliximab and Anti-Infliximab Antibodies**




Frans Kokojka

Postdoctoral Researcher

Ben-Gurion University of the Negev

18h15 • **The Name of the Dose: Analysis of an alerting system for clinicians requesting TDM in a tertiary center**



Andrea Ortiz Dominguez

4th year Clinical Resident in Immunology

Fundación Jiménez Díaz's University Hospital, Department of Immunology, Spain

18h30

POSTER Presentation Session & Cocktail Reception


- Exhibition Hall

20h00

Announcement of "BEST POSTER" Prize

20h30

End of Day 1



Day 2

Wednesday, July 1st 2026

8h00

Welcome coffee

8h20

Radiotherapeutics : Empowering the Next Generation of Antibody Modalities

- Einstein Auditorium

8h20 • Radiolabelled antibody fragments for use in treating cancer



Tony Lahoutte

Head of the department of nuclear medicine

UZ Brussel, Vrije Universiteit Brussel, Belgium

8h50 • Radiolabelled sdAb for radioligand therapy of cancer



Matthias D'Huyvetter

Professor

Vrije Universiteit Brussel, Belgium

9h20 • Antibody-radiolabelled conjugates



Jean-Pierre Pouget

Group Leader

Institut de Recherche en Cancérologie Montpellier (IRCM), France

9h50 • Cell-Free Triage of AI Antibodies Predicts CHO Kinetics



Ryan Nelson

Field Application Scientist

Nuclera, UK

10h00

Coffee Break at Exhibition Hall

Next-Generation 3D Cancer Models and NAMs in Antibody Screening

- Barthez Room

Session in partnership with



8h20 • Organoid cultures / tumoroids for Drug Screening



Guillaume Mottet

Senior Director of Biologics Discovery

Microfluidics Team, SANOFI, France

8h50 • Application of Mature 3D Tumoroids in drug screening and MoA research



Marcin Krzykowski

Founder and CEO

Real Research, Poland

9h20 • New generation of in vitro model: general context, advantages, limitations, and case study on breast and ovarian cancer



Pierre Gaudriault

Chief Business Developer

Antineo, AFSSI, France


9h50 • Improving Monoclonal Antibody PK Predictability Through Comparison of Humanized FcRn Mouse Models



Chloé Beuraud

Research Scientist - Bio PK / Safety Assessment

EVOTEC, France



THE 2026 AGENDA

10h30

ADCS, XDCs& Armed Antibodies: Beyond Classical Conjugates

- Einstein Auditorium

10h30 • **Alternative Drug Conjugates (XDCs) and armed antibodies beyond canonical Antibody Drug Conjugates (ADCs)**



Alain Beck

Senior Director, Biologics CMC & developability

Laboratoires Pierre Fabre, France

11h00 • **Conditional Logic-Gated Bispecific ADC Targeting CD7xCD33 Enables Selective Targeting in High-Risk AML**



Tiffany Thorn

Founder and CEO

BiVictriX Therapeutics, UK

11h30 • **Novel payload for antibody drug conjugate**



Xavier Preville

Co-founder, VP and head of research & preclinical development

Adcytherix, France

12h00 • **A fast and integrated workflow for the discovery of highly internalized anti-HER2 ADCs**



Jacques Fieschi

Chief Scientific Officer

MImAbs, France

12h10

Lunch at Exhibition Hall

Antibodies in Women's Health - Barthez Room

10h30 • **Targeting mesothelial cells for ovarian cancer therapy**



David Pépin

Investigator, Associated Professor

MGBFC Pediatric Surgery Research MGPO, Mass General Research Institute, USA

11h00 • **Pre-clinical development of a blocking anti-Müllerian hormone antibody to treat the polycystic ovary syndrome**



Nathalie Di Clemente Renaud-Besse

Director of Research

Centre de Recherche Saint-Antoine, France

11h30 • **Antibody-based contraception and prevention**



Deborah Anderson

Professor of Medicine and Director of the NIH Contraceptive Development Research Center

Boston University School of Medicine, USA


12h00 • **Allosteric Modulation of FSHR Using Single-Domain Antibody Fragments**



Eric Reiter

Deputy director of UMR PRC, BIOS team

MUSCA team (INRIA/INRAE/CNRS), INRAE Centre Val de Loire, Nouzilly, France



13h00

Workshop by Schrödinger: Leveraging State-of-The-Art In Silico Modeling and Informatics: An End-To-End Biologics Design Workflow From Bioluminate To LiveDesign
- BARTHEZ ROOM



Jelena Vucinic
Senior Scientist, Applications Science
Schrödinger, Germany

Pitch in front of Investors - Private session




Stéphane Legastelois
President & Founder
33 California, France



Marie Chambodut
Associate Managing Director
Angelor, France



Companies presenting



THE 2026 AGENDA

14h00

Clinical Advancement of New Antibody Modalities

- Einstein Auditorium

14h00 • **Engineering Immune Engagement: Novel Multispecific Antibody Formats and Cell-Based Delivery Platforms**



Luis Álvarez-Vallina


Research Director

Banc de Sang i Teixits, Spain

Group Leader

CNIO-HMarBCN Cancer Immunotherapy Clinical Research Unit Spanish National Cancer Research Centre (CNIO), Madrid, Spain Hospital del Mar Research Institute, Barcelona, Spain

14h30 • **ADCs: current scenario and future of cancer therapy**



Rafael Grochot

Medical Oncologist - Clinical Trials Specialist

Sarah Cannon Research Institut, UK

15h00 • **IPH4502, a novel and differentiated Nectin-4 exatecan ADC: preclinical characterization**



Romain Remark

Clinical Program Manager

Innate Pharma, France

15h30 • **Application of the SMO Model - From the development of a new mAbs process to the production of a GMP-compliant batch**



Amel Hadri

CEO and Founder

INITs, France



Stéphane Legastelois

Chairman of the Board

Alga Biologics, France

15h40

Closing Keynote - Einstein Auditorium

15h40 • **Protein engineering across therapeutics and diagnostics**



Andreas Plückthun

Professor of Biochemistry and Director of the Department of Biochemistry

Universität Zürich, Switzerland

16h20

Announcement of AIS2027

16h30

End of Congress

Beyond Oncology : Antibodies for Infection & Brain Disorders

- Barthéz Room

14h00 • **Antiviral antibodies in infectious diseases**



Hugo Mouquet

Head of the Humoral Immunology Unit

Institut Pasteur, France

14h30 • **VHHs as novel therapeutic tools for brain diseases**



Laurent Prézeau

Researcher, Neuroreceptors: Dynamics and Functions

Institut de Génétique Fonctionnelle, France

15h00 • **VHHs for Alzheimer's disease**



Clément Danis

Postdoctoral Researcher

Université de Lille, France

15h30 • **AI De Novo Antibody Generation Targeting CLDN18.2: Computational Design, Expression, and Functional Validation**



Chuanting Tan

Senior R&D Engineer

Tsingke Biotech, China

WORKSHOP by



Bridging Innovation to the Clinic: Smart First-in-Human Dose Selection for Novel Targeted Therapeutics

June 30th 2026 at 13h00 in BARTHEZ ROOM

Selecting an appropriate first-in-human (FIH) dose is a pivotal step in successfully translating innovative therapeutic modalities such as antibody-drug conjugates (ADCs), bispecific antibodies, fusion proteins, gene therapies, antisense oligonucleotides (ASOs) and combination treatments into clinical development.

Traditional dose selection approaches often fall short in addressing the unique pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of these modalities, increasing the risk of suboptimal efficacy or safety concerns.

The primary focus of this workshop will be on **integrated PK/PD modeling-driven approaches combining in-vitro and in-vivo data**, mechanistic insights, and translational strategies to optimize first-in-human dose selection, de-risk early clinical trials, and support regulatory interactions. We will illustrate how these methods extend beyond defining a safe starting dose by enabling prediction of clinically effective doses, onset of action, and duration of treatment effects. Ultimately, this approach supports the design of FIH studies that go beyond safety assessment, enabling efficient dose escalation with a well-justified dose range and study duration, and facilitating a seamless transition to dose-finding studies or even directly into Phase III.

Designed for scientists and decision-makers in preclinical and translational research, this session will offer a clear, strategic framework for using PK/PD modeling to inform FIH study design. Whether you are working on preclinical development, translational strategy, or regulatory interactions, you will leave with actionable insights to enhance decision-making in early-phase drug development.

This workshop will **provide a practical overview of FIH dose selection challenges and solutions**, drawing from real-world examples and the latest modeling strategies. We will demonstrate how PK/PD modeling can integrate preclinical data, mechanistic insights, and translational approaches to optimize dose selection, de-risk early clinical trials, and support regulatory interactions. Beyond identifying a safe starting dose, PK/PD modeling can also predict clinically efficacious doses, time to onset of effect, and effect duration. In this way, FIH studies will not only be safe but feature an efficient dose escalation with an informed top dose and the right study duration, facilitating a seamless transition to dose-finding studies or even directly to Phase III.

Designed for scientists and decision-makers in preclinical and translational research, this session will offer a clear, strategic framework for using PK/PD modeling to inform FIH study design. Whether you are working on preclinical development, translational strategy, or regulatory interactions, you will leave with actionable insights to enhance decision-making in early-phase drug development.

Hosted by



Bastien Casini

Quantitative Systems Pharmacology Modeler
LYO-X, Switzerland



Igor Vostiar

Senior Clinical Pharmacology and PK/PD Expert
LYO-X, Switzerland

THE 2026 WORKSHOPS

WORKSHOP by **Lonza**

From Science to Strategy - Making Biotech Ventures Investment-Ready

June 30th 2026 at 13h00 in PASTEUR ROOM

The French biotech ecosystem is rich in innovation, but for many startups, the preclinical phase is where ambition collides with investor caution. This panel brings together a venture capitalist, early drug development experts in Biologics and Bioconjugates and a Biotech peer to unpack what makes a startup both fundable and feasible from target validation to IND. Gain practical insights into investor expectations, outsourcing strategies, and integrated development approaches that help de-risk your science and build confidence among the strategic partners critical to your next milestones.



Yvette Stallwood
Senior Director, Head of Early Development Services
LONZA, Switzerland



Antoine Thomas
Senior CMC Consultant
ATBio Consulting, France



Laurence Bonnafoux
Director Bioconjugates MSAT
LONZA, Switzerland

Moderated by



Gavin Vuddamalai
Head of Scientific Affairs and Business Intelligence
MabDesign, France

WORKSHOP by **Schrödinger**

Leveraging State-of-The-Art In Silico Modeling and Informatics: An End-To-End Biologics Design Workflow From BioLuminate To LiveDesign

July 1st 2026 at 13h00 in BARTHEZ ROOM

The design and optimization of modern biologics increasingly relies on seamless integration of structural modeling, predictive algorithms, and collaborative informatics platforms. This workshop will demonstrate an end-to-end workflow that brings together the capabilities of the Schrödinger core suite, BioLuminate, and LiveDesign to accelerate biologics discovery and engineering.

We begin in BioLuminate, showcasing a range of modeling capabilities used in early antibody assessment and engineering. **Participants will explore antibody liability and developability analysis, structure-guided ideation, and a series of engineering strategies powered by state-of-the-art free energy methods — including protein FEP+, residue-scanning FEP, and pH-dependent calculations.** These approaches will be demonstrated in the context of practical design questions such as affinity tuning, specificity engineering, and mitigation of liabilities.

The resulting in silico predictions will then be transferred into LiveDesign, where they can be combined with experimental data to support iterative design cycles. **Within LiveDesign, attendees will learn how to analyze multi-modal data, generate hypotheses, perform virtual variant exploration, and prioritize next-step engineering ideas using LiveDesign's collaborative and decision-support environment.**

Hosted by :



Jelena Vucinic
Senior Scientist, Applications Science
Schrödinger, Germany

2026 SCIENTIFIC ADVISORY BOARD



Alain Beck

Senior Director, Biologics CMC & developability
Centre d'Immunologie Pierre Fabre, France



Thierry Wurch

Senior VP Late-Stage Development
Fair Journey Bio, Portugal



Ana Antunes

Head of International Affairs, Scientific Events & Communication
MabDesign, France




Nicolas Poirier

CEO & Founder
TikeoBio, France



Lennart Zabeau

Principal Scientist
Orionis Biosciences, Belgium



Stéphanie Cornen

VP, Investor Relations, Communication & Commercial Strategy
Innate Pharma, France




Francis Duffieux

Principal Scientist – Senior Scientific Coordinator & Expert Large Molecules Research
SANOFI, France



Elisa Fontana

Hospital Medical Director
Sarah Cannon Research Institute, UK



Stefan Zielonka

Prof. Dr., Global Head of Antibody Discovery & Protein Engineering (ADPE)
Merck Healthcare KGaA, Darmstadt, Germany



Maëva Chauvin

Researcher / Instructor
IRCM, France | Harvard Medical School, USA



2026 SCIENTIFIC ADVISORY BOARD



Laurent Gros

Researcher

IRCM, France



Céline Gongora

Group Leader

IRCM, France



Jean-Pierre Pouget

Group Leader

IRCM, France



Pierre Ferré

Chief Operating Officer

Compugen Ltd., Israel



Mar Naranjo-Gomez

Scientific Researcher

IRMB, France



Mireia Pelegrin

Group Lead, CNRS Research Director

IRMB, France



Philippe Rondard

Researcher

IGF, France



Peter Lowe

Director of Antibody Engineering

Merus, Netherlands



Nathalie Corvaia

CEO

NCO Biotech Consulting, France



Nicolas MOUZ

Head of Technology Development, Technology Transfer and Industrial Partnership

Institut Pasteur, France



Join us in 2027

2nd Bioproduction Forum (BIOPF2027)

May 2027 in Lausanne, Switzerland

Pierre-Mehdi Hammoudi

+33 (0)4 78 02 39 89

pierre-mehdi.hammoudi@mabdesign.fr



4th Innovations for Cell and Gene Therapies Congress (ICGT2027)

May 2027 in SANOFI Campus Gentilly, France

Laure Delhon

+33 (0)7 69 85 65 56

laure.delhon@mabdesign.fr



15th Antibody Industrial Symposium (AIS2027)

June 23-24 2027 in Tours, France

Ana Antunes

+33 (0)7 59 56 52 76

ana-sofia.antunes@mabdesign.fr



12th Bioproduction Congress (BIOPC2027)

September 2027 in Lyon, France

Pierre-Mehdi Hammoudi

+33 (0)4 78 02 39 89

pierre-mehdi.hammoudi@mabdesign.fr



11th Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2026)

October 2027 in Lyon, France

Laure Delhon

+33 (0)7 69 85 65 56

laure.delhon@mabdesign.fr